Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy

[1]  Jeffrey T. Chang,et al.  Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer , 2021, Clinical Cancer Research.

[2]  Peter H. Hu,et al.  Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis , 2020, Cancer Research.

[3]  J. Buján,et al.  Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR , 2020, Journal of oncology.

[4]  A. Salomon,et al.  Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers , 2020, Journal of Hematology & Oncology.

[5]  N. Turner,et al.  Targeting the PI3-kinase pathway in triple negative breast cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  K. Hess,et al.  Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. , 2018, The oncologist.

[7]  K. Hess,et al.  Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab , 2017, JAMA oncology.

[8]  D. Sabatini,et al.  mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.

[9]  Mei Liu,et al.  Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Harold L. Moses,et al.  Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection , 2016, PloS one.

[11]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[12]  R. O'Regan,et al.  The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers , 2014, Therapeutic advances in medical oncology.

[13]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[14]  J. Pietenpol,et al.  Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes , 2014, The Journal of pathology.

[15]  Hans-Peter Sinn,et al.  A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition , 2013, Breast Care.

[16]  Stephen T. C. Wong,et al.  Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer , 2013, Clinical Cancer Research.

[17]  M. Simon,et al.  PRR5L degradation promotes MTORC2-mediated PKCδ phosphorylation and cell migration downstream of Gα12 , 2012, Nature Cell Biology.

[18]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[19]  Yanhong Zhang,et al.  Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition , 2012, Modern Pathology.

[20]  M. Wicha,et al.  Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia , 2012, Proceedings of the National Academy of Sciences.

[21]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[22]  J. Lee,et al.  The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients , 2011, Breast Cancer Research and Treatment.

[23]  N. Harbeck,et al.  Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials , 2010, British Journal of Cancer.

[24]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[25]  Kakajan Komurov,et al.  Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes , 2010, Proceedings of the National Academy of Sciences.

[26]  Nicholas J. Wang,et al.  Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. , 2009, Cancer research.

[27]  Christos Hatzis,et al.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  G. von Minckwitz,et al.  The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial , 2006, British Journal of Cancer.

[29]  G. Hortobagyi,et al.  Biphasic metaplastic sarcomatoid carcinoma of the breast. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  G. Hortobagyi,et al.  Sarcomatoid (metaplastic) carcinoma of the breast: The U.T. M.D. Anderson Cancer Center (MDACC) and SEER database experience , 2005 .

[31]  T. Chao,et al.  Metaplastic carcinomas of the breast , 1999, Journal of surgical oncology.

[32]  H. Norris,et al.  Metaplastic carcinomas of the breast: V. Metaplastic carcinoma with osteoclastic giant cells. , 1990, Human pathology.

[33]  H. Norris,et al.  Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin , 1990, Cancer.

[34]  H. Norris,et al.  Metaplastic carcinomas of the breast. III. Carcinosarcoma , 1989, Cancer.

[35]  H. Norris,et al.  Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. , 1989, Human pathology.

[36]  H. Norris,et al.  Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. , 1989, Human pathology.

[37]  M. Massobrio,et al.  Metaplastic breast carcinoma: pathology and clinical outcome. , 2003, Anticancer research.